Page 70 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

oligonucleotides. J Med Chem. 2016;59(21):9645-9667. conjugates and their antimicrobial applications-a mini-
review. Eur Biophys J. 2023;52:533-544.
doi: 10.1021/acs.jmedchem.6b00551
doi: 10.1007/s00249-023-01673-w
112. Yavin E. Peptide nucleic acids: Applications in biomedical
sciences. Molecules. 2020;25(15):3317. 123. Available from: https://www.olipass.com/front/eng/
competitive/pipeline.do [Last accessed on 2024 July 05].
doi: 10.3390/molecules25153317
124. Glatz JFC, Luiken J. Dynamic role of the transmembrane
113. Hansen AM, Bonke G, Hogendorf WFJ, et al. Microwave-
assisted solid-phase synthesis of antisense acpP peptide glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and
nucleic acid-peptide conjugates active against colistin- and utilization. J Lipid Res. 2018;59(7):1084-1093.
tigecycline-resistant E. coli and K. pneumoniae. Eur J Med doi: 10.1194/jlr.R082933
Chem. 2019;168:134-145.
125. Glatz JF, Luiken JJ. From fat to FAT (CD36/SR-B2):
doi: 10.1016/j.ejmech.2019.02.024 Understanding the regulation of cellular fatty acid uptake.
Biochimie. 2017;136:21-26.
114. Klabenkova K, Fokina A, Stetsenko D. Chemistry of
peptide-Oligonucleotide conjugates: A review. Molecules. doi: 10.1016/j.biochi.2016.12.007
2021;26(17):5420.
126. Wang L, Wang YS, Mugiyanto E, Chang WC, Yvonne
doi: 10.3390/molecules26175420 Wan YJ. MiR-22 as a metabolic silencer and liver tumor
suppressor. Liver Res. 2020;4(2):74-80.
115. Li C, Zhang G, Mohapatra S, et al. Machine learning guides
peptide nucleic acid flow synthesis and sequence design. doi: 10.1016/j.livres.2020.06.001
Adv Sci (Weinh). 2022;9(34):e2201988.
127. Paul D, Miller MH, Born J, et al. The promising therapeutic
doi: 10.1002/advs.202201988 potential of oligonucleotides for pulmonary fibrotic diseases.
Expert Opin Drug Discov. 2023;18(2):193-206.
116. Li C, Callahan AJ, Phadke KS, et al. Automated flow
synthesis of peptide-PNA conjugates. ACS Cent Sci. doi: 10.1080/17460441.2023.2160439
2022;8(2):205-213.
128. Bao X, Liang Y, Chang H, et al. Targeting proprotein
doi: 10.1021/acscentsci.1c01019 convertase subtilisin/kexin type 9 (PCSK9): From bench to
bedside. Signal Transduct Target Ther. 2024;9(1):13.
117. Hammond SM, Aartsma-Rus A, Alves S, et al. Delivery
of oligonucleotide-based therapeutics: Challenges and doi: 10.1038/s41392-023-01690-3
opportunities. EMBO Mol Med. 2021;13(4):e13243.
129. Katsiki N, Vrablik M, Banach M, Gouni-Berthold I.
doi: 10.15252/emmm.202013243 Inclisiran, Low-density lipoprotein cholesterol and
lipoprotein (a). Pharmaceuticals (Basel). 2023;16(4):577.
118. McCartan R, Khorkova O, Volmar CH, Wahlestedt C.
Nucleic acid-based therapeutics for the treatment of central doi: 10.3390/ph16040577
nervous system disorders. Front Genet. 2023;14:1250276.
130. Huang HYR, Badar S, Said M, et al. The advent of RNA-
doi: 10.3389/fgene.2023.1250276 based therapeutics for metabolic syndrome and associated
conditions: A comprehensive review of the literature. Mol
119. Baker BF, Xia S, Partridge W, et al. Safety and tolerability of
GalNAc -conjugated antisense drugs compared to the same- Biol Rep. 2024;51(1):493.
3
sequence 2’-O-Methoxyethyl-modified antisense drugs: doi: 10.1007/s11033-024-09457-x
Results from an integrated assessment of phase 1 clinical 131. Nappi F, Avtaar Singh SS, Jitendra V, Alzamil A, Schoell T.
trial data. Nucleic Acid Ther. 2024;34:18-25.
The Roles of microRNAs in the Cardiovascular System. Int J
doi: 10.1089/nat.2023.0026 Mol Sci. 2023;24(18):14277.
120. Sarkar S, Colon-Roura G, Pearse A, Armitage BA. doi: 10.3390/ijms241814277
Targeting a KRAS i-motif forming sequence by unmodified 132. Lobstein T. World Obesity Atlas 2024; 2024. Available from:
and gamma-modified peptide nucleic acid oligomers. https://data.worldobesity.org/publications/?cat=22 [Last
Biopolymers. 2023;114(1):e23529.
accessed 2024 July 05].
doi: 10.1002/bip.23529
133. Yang Z, Wang L. Current, emerging, and potential therapies
121. Wickline SA, Hou KK, Pan H. Peptide-based nanoparticles for non-alcoholic steatohepatitis. Front Pharmacol.
for systemic extrahepatic delivery of therapeutic nucleotides. 2023;14:1152042.
Int J Mol Sci. 2023;24(11):9455.
doi: 10.3389/fphar.2023.1152042
doi: 10.3390/ijms24119455
134. Knerr PJ, Mowery SA, Douros JD, et al. Next generation
122. Tsylents U, Siekierska I, Trylska J. Peptide nucleic acid GLP-1/GIP/glucagon triple agonists normalize body weight

Volume 7 Issue 3 (2024) 17 doi: 10.36922/itps.3025